Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (400)	12/20/2003 3:03:15 AM
From: Icebrg	Read Replies (3) \| Respond to of 824

Yes, that's right. This is an extremely favorable deal for MLNM. XOMA has to take all the early-stage development risks and costs, but still has to hand the product back to MLNM after completing phase II studies. If things look good, MLNM can proceed, if not they just drop it. I wish all their development deals looked like this. Until now, no-one wanted to spend anything taking this drug into the clinic. XOMA must have seen something no-one else saw to accept this type of arrangement. I wonder what. Erik